90 related articles for article (PubMed ID: 12820323)
1. Cyfra 21-1 in diagnosis of distant metastases of head and neck carcinoma.
Hoffmann-Fazel A; Hoffmann M; Gottschlich S; Maass JD; Rudert H; Maune S
Anticancer Res; 2003; 23(2A):917-20. PubMed ID: 12820323
[TBL] [Abstract][Full Text] [Related]
2. Cyfra 21-1: a serological help for detection of distant metastases in head and neck cancer.
Maass JD; Hoffmann-Fazel A; Goeroegh T; Hoffmann M; Meyer JE; Gottschlich S; Rudert H; Maune S
Anticancer Res; 2000; 20(3B):2241-3. PubMed ID: 10928185
[TBL] [Abstract][Full Text] [Related]
3. Analytical and clinical evaluation of CYFRA 21-1 by electrochemiluminescent immunoassay in head and neck squamous cell carcinoma.
Deng YF; Chen P; Lin YZ; Le JZ; Wu XL; Yu MQ; Zhuang PY; Gao MH
J Laryngol Otol; 2003 Mar; 117(3):190-4. PubMed ID: 12648374
[TBL] [Abstract][Full Text] [Related]
4. Follow-up with serum Cyfra 21-1 in patients with squamous cell carcinomas of the head and neck.
Kuropkat C; Lippert BM; Werner JA
Oncology; 2002; 63(3):280-5. PubMed ID: 12381908
[TBL] [Abstract][Full Text] [Related]
5. [Analysis of risk factors in the prediction of distant metastases of head and neck squamous cell carcinomas].
Li XM; Di B; Shang YD; Zhou YQ; Ma HM; Cheng JM
Zhonghua Er Bi Yan Hou Ke Za Zhi; 2004 Mar; 39(3):171-5. PubMed ID: 15283298
[TBL] [Abstract][Full Text] [Related]
6. The prognostic value of the tumour marker Cyfra 21-1 in carcinoma of head and neck and its role in early detection of recurrent disease.
Doweck I; Barak M; Uri N; Greenberg E
Br J Cancer; 2000 Dec; 83(12):1696-701. PubMed ID: 11104568
[TBL] [Abstract][Full Text] [Related]
7. [Study of Cyfra 21-1 as a new tumor marker for the diagnosis of epidermoid carcinoma of the head and neck].
González Sánchez E; López-Ríos Velasco J; Calvo Boizas E; García-Talavera Fernández JR; Martín Ro-dríguez M; Muñoz Herrera A; Del Cañizo Alvarez A
Acta Otorrinolaringol Esp; 1999 Mar; 50(2):85-9. PubMed ID: 10217679
[TBL] [Abstract][Full Text] [Related]
8. The significance of ferritin, lipid-associated sialic acid, CEA, squamous cell carcinoma (SCC) antigen, and CYFRA 21-1 levels in SCC of the head and neck.
Inal E; Laçin M; Asal K; Ceylan A; Köybaşioğlu A; Ileri F; Uslu SS
Kulak Burun Bogaz Ihtis Derg; 2004; 12(1-2):23-30. PubMed ID: 16010093
[TBL] [Abstract][Full Text] [Related]
9. Clinical significance of micrometastatic cells detected by E48 (Ly-6D) reverse transcription-polymerase chain reaction in bone marrow of head and neck cancer patients.
Colnot DR; Nieuwenhuis EJ; Kuik DJ; Leemans CR; Dijkstra J; Snow GB; van Dongen GA; Brakenhoff RH
Clin Cancer Res; 2004 Dec; 10(23):7827-33. PubMed ID: 15585614
[TBL] [Abstract][Full Text] [Related]
10. Combined use of established and novel tumour markers in the diagnosis of head and neck squamous cell carcinoma.
Ayude D; Gacio G; Páez de la Cadena M; Pallas E; Martínez-Zorzano VS; de Carlos A; Rodríguez-Berrocal FJ
Oncol Rep; 2003; 10(5):1345-50. PubMed ID: 12883705
[TBL] [Abstract][Full Text] [Related]
11. Comparison of CYFRA 21-1 and tissue polypeptide specific antigen (TPS) for detecting nasopharyngeal carcinoma.
Tai CJ; Liu FY; Liang JA; Yang SN; Tsai MH; Kao CH
Anticancer Res; 2002; 22(6B):3793-6. PubMed ID: 12552995
[TBL] [Abstract][Full Text] [Related]
12. Detection of serum Cyfra 21-1 in patients with primary oral squamous cell carcinoma.
Zhong LP; Zhu HG; Zhang CP; Chen WT; Zhang ZY
Int J Oral Maxillofac Surg; 2007 Mar; 36(3):230-4. PubMed ID: 16965897
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathologic risk factors for distant metastases from head and neck squamous cell carcinomas.
Li X; Di B; Shang Y; Zhou Y; Cheng J; He Z
Eur J Surg Oncol; 2009 Dec; 35(12):1348-53. PubMed ID: 19616915
[TBL] [Abstract][Full Text] [Related]
14. Clinical usefulness of CYFRA 21-1 for esophageal squamous cell carcinoma in radiation therapy.
Wakatsuki M; Suzuki Y; Nakamoto S; Ohno T; Ishikawa H; Kiyohara H; Kiyozuka M; Shirai K; Nakayama Y; Nakano T
J Gastroenterol Hepatol; 2007 May; 22(5):715-9. PubMed ID: 17444861
[TBL] [Abstract][Full Text] [Related]
15. Detection of occult bone metastases from head and neck squamous cell carcinoma: impact of positron emission tomography computed tomography with fluorodeoxyglucose F 18.
Basu D; Siegel BA; McDonald DJ; Nussenbaum B
Arch Otolaryngol Head Neck Surg; 2007 Aug; 133(8):801-5. PubMed ID: 17709620
[TBL] [Abstract][Full Text] [Related]
16. Detection of micrometastatic tumor cells in head and neck squamous cell carcinoma. A possible predictor of recurrences?
Guney K; Yoldas B; Ozbilim G; Derin AT; Sarihan S; Balkan E
Saudi Med J; 2007 Feb; 28(2):216-20. PubMed ID: 17268699
[TBL] [Abstract][Full Text] [Related]
17. Soluble CD44 is a potential marker for the early detection of head and neck cancer.
Franzmann EJ; Reategui EP; Pedroso F; Pernas FG; Karakullukcu BM; Carraway KL; Hamilton K; Singal R; Goodwin WJ
Cancer Epidemiol Biomarkers Prev; 2007 Jul; 16(7):1348-55. PubMed ID: 17627000
[TBL] [Abstract][Full Text] [Related]
18. Cyfra 21-1 as a serum tumor marker for follow-up of patients with laryngeal and hypopharyngeal squamous cell carcinoma.
Al-Shagahin H; Alkotyfan K; Müller HH; Sesterhenn AM; Werner JA
Anticancer Res; 2009 Aug; 29(8):3421-5. PubMed ID: 19661367
[TBL] [Abstract][Full Text] [Related]
19. Cyfra 21.1, TPS and SCC in squamous cell carcinoma of larynx.
Monteiro E; Varzim G; Crespo M; Araújo L
An Otorrinolaringol Ibero Am; 2003; 30(5):467-79. PubMed ID: 14648927
[TBL] [Abstract][Full Text] [Related]
20. Clinical significance of micrometastases detection in lymph nodes from head and neck squamous cell carcinoma.
Xu Y; Lefèvre M; Périé S; Tao L; Callard P; Bernaudin JF; St Guily JL
Otolaryngol Head Neck Surg; 2008 Sep; 139(3):436-41. PubMed ID: 18722227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
